The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
Header
News Archive
Showing 48 results
August 2024
-
Story Global Impact
Enabling early detection of psoriatic arthritis
-
Story Global Impact
Biomarker research to help modernize care in multiple sclerosis
-
Story Global Impact
My Krew
-
Media Release
Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy
Prioritization of screening programs for spinal muscular atrophy (SMA) will ensure early diagnosis across Canada and bring lasting impact to babies and caregivers Montreal, August 20, 2024 —…
May 2024
-
Media Release
NOVARTIS CANADA AND CLARIUS MOBILE HEALTH CHALLENGE STANDARD OF CARE FOR PSORIATIC ARTHRITIS WITH NEW PARTNERSHIP
Psoriatic arthritis is a chronic, autoimmune disease form of arthritis that causes joint inflammation (swelling, pain, stiffness) and occurs with skin condition psoriasis. It can also affect the… -
Media Release
Health Canada approves Cosentyx®, a biologic therapy, for the treatment of adults with moderate to severe Hidradenitis Suppurativa (HS)
Approval is based on the two largest Phase III trials conducted in HS – SUNSHINE and SUNRISE – demonstrating the safety and efficacy of Cosentyx® in HS1HS is a chronic, immunological, inflammatory…
March 2024
-
Media Release
Health Canada grants approval of the Eye-Tracking Neurological Assessment for Multiple Sclerosis (ETNA™-MS) for use in tracking disease progression in people living with MS
More than 90,000 Canadians—or one in 400 people across Canada—live with multiple sclerosis (MS),1 a neurodegenerative, chronic condition that affects the central nervous system.2Despite decades… -
Media Release
Novartis Canada’s statement on CADTH draft recommendations for LEQVIO® (inclisiran)
Montréal, QC, March 21, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by…